Endpoints News has released a poll regarding the Food and Drug Administration’s approval of aducanumab for use in Alzheimer’s disease. The drug, made by Biogen, has led to a wide range of criticism regarding focusing on its uncertain data and high price tag.
“If there’s one thing that’s absolutely clear in the dustup over the aducanumab approval, it’s that most everyone who can register an opinion has fired off something, somewhere. Now it’s your turn as we size up the biopharma industry’s mood on this important issue. We’ve assembled a set of 4 questions for this industry survey gauging your opinion on the FDA’s actions involving one of the most controversial decisions the agency has ever handed down.” Take the survey here.
(Source: John Carroll, Endpoints News, 6/8/21)